Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: bentway who wrote (615782)	6/11/2011 1:42:03 PM
From: TopCat	2 Recommendations Respond to of 1579868

"Something not mentioned in the article - Walmart cut generic drug prices to $4 a month for hundred of generic prescriptions, and all other national pharmacy chains HAD to follow suit. Any senior that can do basic math knows that that's EVEN CHEAPER than Part D. Any brand name prescription (but for a very few like insulin) can be swapped for one of these generics, with no ill effects. I'd say this had an even greater effect than the reasons cited in the article, and explains the low participation in part D. As seniors communicate this - I'd expect participation to become even lower." That's called competition....

To: bentway who wrote (615782)	6/11/2011 2:24:44 PM
From: i-node	Read Replies (1) \| Respond to of 1579868

>> Something not mentioned in the article - Walmart cut generic drug prices to $4 a month for hundred of generic prescriptions, and all other national pharmacy chains HAD to follow suit. Any senior that can do basic math knows that that's EVEN CHEAPER than Part D. Any brand name prescription (but for a very few like insulin) can be swapped for one of these generics, with no ill effects. True. According to the Kaiser Family Foundation study from 2007, the Part D donut hole (eliminated by Obamacare) was a driving force behind the switch to generics. Coincidentally, it likely accounts for some of the decline in innovation, since generics are now a more profitable business than before.